SHNX.Y Stock Overview Through its subsidiaries, develops, manufactures, and sells bulk pharmaceuticals, preparations, and chemical products in the People's Republic of China, the Americas, Europe, and internationally. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Shandong Xinhua Pharmaceutical Company Limited Competitors Price History & Performance
Summary of share price highs, lows and changes for Shandong Xinhua Pharmaceutical Historical stock prices Current Share Price HK$18.19 52 Week High HK$18.19 52 Week Low HK$18.19 Beta 0.095 1 Month Change 0% 3 Month Change n/a 1 Year Change n/a 3 Year Change n/a 5 Year Change n/a Change since IPO 0%
Recent News & Updates
Shandong Xinhua Pharmaceutical Company Limited to Report Fiscal Year 2024 Results on Mar 31, 2025 Dec 31
Shandong Xinhua Pharmaceutical Company Limited (SEHK:719) signed an equity acquisition intention agreement to acquire 75% stake in Novosana (Taicang) Bio Feed Co., Ltd. from Novosana (Europe) B.V. Dec 12
Shandong Xinhua Pharmaceutical Company Limited Announces Calcium Gluconate Injection Passing the Generics Consistency Evaluation Nov 05
Shandong Xinhua Pharmaceutical Company Limited Obtains FDA Approval of Abbreviated New Drug Application Oct 28
Shandong Xinhua Pharmaceutical Company Limited to Report Q3, 2024 Results on Oct 30, 2024 Sep 30
Shandong Xinhua Pharmaceutical Company Limited Announces Interim Cash Dividend of the Year 2024 of A Shares, Payable on 27 September 2024 Sep 21 See more updates
Shandong Xinhua Pharmaceutical Company Limited to Report Fiscal Year 2024 Results on Mar 31, 2025 Dec 31
Shandong Xinhua Pharmaceutical Company Limited (SEHK:719) signed an equity acquisition intention agreement to acquire 75% stake in Novosana (Taicang) Bio Feed Co., Ltd. from Novosana (Europe) B.V. Dec 12
Shandong Xinhua Pharmaceutical Company Limited Announces Calcium Gluconate Injection Passing the Generics Consistency Evaluation Nov 05
Shandong Xinhua Pharmaceutical Company Limited Obtains FDA Approval of Abbreviated New Drug Application Oct 28
Shandong Xinhua Pharmaceutical Company Limited to Report Q3, 2024 Results on Oct 30, 2024 Sep 30
Shandong Xinhua Pharmaceutical Company Limited Announces Interim Cash Dividend of the Year 2024 of A Shares, Payable on 27 September 2024 Sep 21
Shandong Xinhua Pharmaceutical Company Limited Receives Notification of Approval of Supplementary Drug Application Sep 13
Shandong Xinhua Pharmaceutical Company Limited Announces Esomeprazole Magnesium Obtains the Notification of Approval of Marketing Application for Chemical Substance Drugs Sep 02
Shandong Xinhua Pharmaceutical Company Limited Announces Interim Dividend, Payable on or Before 27 September 2024 Aug 22
Shandong Xinhua Pharmaceutical Company Limited Announces Final Profit Distribution Plan to Be Implemented on A Shares for the Year 2023, Payable on 30 July 2024 Jul 24
Shandong Xinhua Pharmaceutical Company Limited to Report First Half, 2024 Results on Aug 23, 2024 Jun 29
Shandong Xinhua Pharmaceutical Company Limited Approves Final Cash Dividend for the Year Ended 31 December 2023, Payable on 30 July 2024 Jun 26
Shandong Xinhua Pharmaceutical Company Limited, Annual General Meeting, Jun 26, 2024 May 29
Shandong Xinhua Pharmaceutical Company Limited to Report Q1, 2024 Results on Apr 26, 2024 Mar 30
Shandong Xinhua Pharmaceutical Company Limited Proposes Final Dividend for the Year Ended 31 December 2023 Mar 28
Shandong Xinhua Pharmaceutical Company Limited Receives Notification of Approval of Application for Marketing of Active Pharmaceutical Ingredient Feb 28
Shandong Xinhua Pharmaceutical Company Limited Announces on Memantine Hydrochloride Tablets Obtaining the Drug Registration Certificate Jan 19
Shandong Xinhua Pharmaceutical Company Limited to Report Fiscal Year 2023 Results on Mar 29, 2024 Dec 30
Shandong Xinhua Pharmaceutical Company Limited Announces Executive Changes Dec 26
Shandong Xinhua Pharmaceutical Company Limited Receives Drug Registration Certificate of levamlodiping besylate tablets (2.5mg) Dec 15
Shandong Xinhua Pharmaceutical Company Limited Announces Approval of Marketing Application for Chemical Raw Material Drugs for Drugsof Febuxostat Oct 11
Shandong Xinhua Pharmaceutical Company Limited Receives the Drug Registration Certificate of Alogliptin Benzoate Tablets Approved and Issued by the National Medical Products Administration Aug 12
Shandong Xinhua Pharmaceutical Company Limited Announces Resignation of Ling Peixue as Independent Non-Executive Director and Member of Strategic Development Committee and Remuneration and Examination Committee Jul 27
Shandong Xinhua Pharmaceutical Company Limited Announces Final Dividend on A Shares for the Year 2022, Payable on July 26, 2023 Jul 22 Shandong Xinhua Pharmaceutical Company Limited Announces Rabeprazole Sodium Enteric-coated Tablets (20mg) Passing the GenericsConsistency Evaluation Jul 15
Shandong Xinhua Pharmaceutical Company Limited Announces on New Drug Specifications and Passing the Generics Consistency Evaluation Jul 11
Shandong Xinhua Pharmaceutical Company Limited Obtains Alogliptin Benzoate Approval of Marketing Application for Chemical Raw Material Drugs Jun 21
Shandong Xinhua Pharmaceutical Company Limited Receives Notice of Approval of Supplementary Drug Application from the National Medical Products Administration Jun 14
Shandong Xinhua Pharmaceutical Company Limited, Annual General Meeting, Jun 26, 2023 May 25
Shandong Xinhua Pharmaceutical Company Limited, Annual General Meeting, Jun 26, 2023 May 24 Shareholder Returns SHNX.Y US Pharmaceuticals US Market 7D 0% -0.03% 1.3% 1Y n/a 1.8% 24.4%
See full shareholder returns
Return vs Market: Insufficient data to determine how SHNX.Y performed against the US Market .
Price Volatility Is SHNX.Y's price volatile compared to industry and market? SHNX.Y volatility SHNX.Y Average Weekly Movement n/a Pharmaceuticals Industry Average Movement 10.7% Market Average Movement 6.4% 10% most volatile stocks in US Market 18.6% 10% least volatile stocks in US Market 3.2%
Stable Share Price: SHNX.Y has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine SHNX.Y's volatility change over the past year.
About the Company Shandong Xinhua Pharmaceutical Company Limited, through its subsidiaries, develops, manufactures, and sells bulk pharmaceuticals, preparations, and chemical products. It operates through Chemical bulk drugs, Preparations, and Chemical intermediates and Others segments. The company offers active pharmaceutical ingredients, pharmaceutical preparations, and chemical products, such as antipyretic analgesics; drugs for cardiovascular and cerebrovascular diseases; anti-infectives; drugs for diseases related to the central nervous system; and other drugs under the Xinhua brand.
Show more Shandong Xinhua Pharmaceutical Company Limited Fundamentals Summary How do Shandong Xinhua Pharmaceutical's earnings and revenue compare to its market cap? SHNX.Y fundamental statistics Market cap US$2.00b Earnings (TTM ) US$51.78m Revenue (TTM ) US$1.03b
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) SHNX.Y income statement (TTM ) Revenue CN¥7.07b Cost of Revenue CN¥5.30b Gross Profit CN¥1.77b Other Expenses CN¥1.41b Earnings CN¥356.66m
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
Mar 24, 2023
Earnings per share (EPS) 0.53 Gross Margin 25.02% Net Profit Margin 5.04% Debt/Equity Ratio 22.9%
How did SHNX.Y perform over the long term?
See historical performance and comparison Dividends
2.7% Current Dividend Yield
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2023/03/19 10:51 End of Day Share Price 2022/12/20 00:00 Earnings 2022/09/30 Annual Earnings 2021/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Shandong Xinhua Pharmaceutical Company Limited is covered by 3 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Alex Fan GF Securities (Hong Kong) Brokerage Limited Ming Li Industrial Securities Co. Ltd. Guohe Fan Phillip Securities (HK)
Show 0 more analysts 